Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2015-04-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于为子公司提供贷款担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the board of directors of 马应龙药业集团股份有限公司 regarding the provision of loan guarantees to its subsidiaries. It details the guarantee amounts, the financial status of the subsidiaries, the board's approval, and compliance with regulatory requirements. The document is a formal disclosure of a financing-related activity (loan guarantees) rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on capital/financing updates related to guarantees. The document length is about 2,036 characters, which is typical for an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-04-24 Chinese
关于公司控股股东及其他关联方占用资金情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement issued by a certified public accounting firm regarding the non-operating funds occupied by the controlling shareholder and other related parties of Mayinglong Pharmaceutical Group Co., Ltd. for the fiscal year ended December 31, 2014. It references the audit report issued on April 23, 2015, and includes a detailed summary table of the non-operating funds occupied and other related party transactions. The document is not a full annual report or interim report but a standalone audit-related disclosure focusing on related party fund occupation, which aligns with the definition of an Audit Report / Information (AR). It is not merely an announcement or certification but contains substantive audited financial data related to the audit of related party transactions. Therefore, the appropriate classification is AR with high confidence.
2015-04-24 Chinese
第八届董事会第七次会议决议公告
Annual Report Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 8th Board of Directors 7th meeting of Mayinglong Pharmaceutical Group Co., Ltd. It includes approval of various reports such as the General Manager's Work Report, Board Work Report, Independent Directors' Report, Audit Committee Report, 2014 Financial Statements, Profit Distribution Plan, Annual Report and Summary, Internal Control Evaluation Report, Social Responsibility Report, and appointment of auditors. It also contains financial data for 2014, including revenue, net profit, assets, and cash flow, as well as dividend distribution details. The document is not merely an announcement of a report but contains substantive financial data and management decisions. The presence of comprehensive financial results and management reports indicates this is a full Annual Report or equivalent. The document length is 3198 characters, which is relatively short but contains detailed financial and operational information, consistent with an Annual Report in the Chinese regulatory context. Therefore, the best fitting category is Annual Report (10-K). FY 2014
2015-04-24 Chinese
2015年第一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2015 年第一季度报告" which translates to "2015 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2015. The report is unaudited as stated in the text. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is about 15,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is IR with high confidence. Q1 2015
2015-04-24 Chinese
2014年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2014 by the independent directors of 马应龙药业集团股份有限公司. It details the independent directors' duties, attendance at board and committee meetings, their opinions on related party transactions, guarantees, and other governance matters during the year. It includes evaluations of internal controls, information disclosure, and overall performance of the board from the perspective of independent directors. The document is a detailed report on board/management oversight and governance activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a proxy, voting result, or regulatory filing. The content aligns with Board/Management Information (MANG) as it focuses on board activities and independent directors' duties and opinions for the year 2014.
2015-04-24 Chinese
2014年度审计报告
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets and profit and loss statements for the years ending December 31, 2014 and 2013. It includes line items such as assets, liabilities, equity, revenues, costs, and expenses, with notes referenced (e.g., (七) 1, (七) 2, etc.). The presence of comprehensive financial data and multiple years' comparative figures indicates this is a full annual financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. The content matches the characteristics of an Annual Report (10-K) rather than an interim report or earnings release. Therefore, the appropriate classification is Annual Report (10-K).
2015-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.